MedWatch

Biotech firm gets Chinese patent on plant substance cocktail for diabetes, obesity and fatty liver prevention

Chinese authorities have issued a patent to French biotech firm Valbiotis which will use plant substances to prevent a series of cardiometabolic illnesses such as diabetes and obesity.

Photo: Malina Petr/AP/Ritzau Scanpix

French biotech company Valbiotis has ensured patent protection in China for the company's active ingredient TOTUM-63 which has shown effects on a series of risk factors for type 2 diabetes, for example, according to a press statement from the firm.

Since its foundation in 2014, Valbiotis has worked with nutrition healthcare and the prevention of type 2 diabetes, obesity cardiovascular illnesses and nonalcoholic fatty liver disease (NASH).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs